Of the 286 lenalidomide-treated patients in MDS-003 and MDS-004, 201 had IPSS and IPSS-R scores available. Median age was 70 years (range 36–95), median time since diagnosis was 2.7 years (range ...
A well-regarded tool for predicting prognosis in myelodysplastic syndromes is updated to incorporate mutations and tested with real-world data. An abstract and poster presented at the 2023 American ...
As such, important advancements have been made toward the dissection of MDS clinical heterogeneity that have incorporated both clinical and molecular characteristics. In this review, we will discuss ...
Subgroup analyses showed consistently higher transfusion independence (TI) response rates than placebo across different risk groups regardless of International Prognostic Scoring System (IPSS), ...
Bristol Myers Squibb has announced positive topline results from its phase 3 trial of Reblozyl (luspatercept-aamt), the first erythroid maturation agent for first-line treatment of patients with very ...
The IPSS-R for MDS currently classifies disease from very low-risk to very high-risk using cytogenetics, BM blasts, and laboratory parameters including hemoglobin, platelets, and absolute neutrophil ...
Risk scoring methods continue to evolve with increased understanding of the factors that affect specific patient group outcomes in MDS. Diagnosis of MDS is currently based on morphology, but can be ...
Somatic MDS mutations occur in five major categories, including RNA splicing, DNA methylation, activated cell signaling, myeloid transcription factors, and chromatin modifiers. Although many MDS cases ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback